Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5811416A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | May 8, 1995 |
| Grant date | Sep 22, 1998 |
| Priority date | — |
| Expiry date | May 8, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical composition for and methods of treatment of menstrual disorders, e.g., dysmenorrhea, in a non-pregnant female, preterm labor, preeclampsia and/or fetal growth retardation in a pregnant female mammal, treatment of atherosclerotic vascular disease and hypertension in males as well as females, and for hormone replacement therapy in peri- and post-menopausal females, comprising administering effective amounts of an endothelin antagonist and/or an endothelin synthase inhibitor or both, in combination with PA1 a progestin, and/or an estrogen, and/or PA1 a cyclooxygenase inhibitor, and/or PA1 a nitric oxide donor and/or nitric oxide substrate, to prevent and/or ameliorate said conditions, are disclosed. In the method aspects, the endothelin antagonist and/or endothelin synthase inhibitor can be administered alone for treatment of menstrual disorders, e.g., dysmenorrhea, in a non-pregnant female, preterm labor, preeclampsia and/or fetal growth retardation in a pregnant female mammal. Further, methods for screening compounds for such treatments are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.